Following are the notable big biotech gainers on Wednesday:-
PDS Biotechnology Corporation (NASDAQ: PDSB) was the notable gainer and soared 21.54%. Last week, the company announced publication of abstract #2501 by the American Society of Clinical Oncology (ASCO). The abstract summarizing interim data from the National Cancer Institute (NCI)-led phase 2 trial has been accepted for oral presentation at the 2021 ASCO Annual Meeting taking place June 4-8. The presentation, scheduled for June 7, is expected to include results from a larger sample than the 14 patients included in the abstract.
Kintara TherapeuticsInc (NYSEAMERICAN: KTRA) stock gained over 17.23% to $1.74 after the company announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research registrational Phase 2/3 trial for glioblastoma multiforme (GBM) has been activated. The trial, titled GBM AGILE, is a patient-centered, adaptive platform trial for registration evaluating multiple therapies for newly diagnosed and recurrent GBM.
The trial plans to enroll 150-200 patients in the Kintara arm of the study at 30 sites in the U.S. and Canada, potentially increasing this total to 40 clinical trial centers.
Jaguar Health (NASDAQ: JAGX) is up 11% to close at $1.68. The company announced today the appointment of Darlene Horton, M.D., a biopharmaceutical veteran and leading clinical development expert, to the role of Chief Medical Officer (CMO) for Napo.
“We are thrilled that Darlene is bringing her strong clinical experience together with deep industry experience and operational leadership, which will support Napo’s ongoing phase 3 clinical trial with crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted cancer therapy (“cancer therapy‑related diarrhea” (CTD)),” said Pravin Chaturvedi, PhD, Napo/Jaguar Chair, Scientific Advisory Board and acting Chief Scientific Officer.
